[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349590-105":59,"doc-detail-349590-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","small-molecule-rasraf-inhibitors-target-ras-driven-cancers-via-allosteric-raf-disruption","Small-molecule RAS/RAF inhibitors target RAS-driven cancers via allosteric RAF disruption","","RAS is a frequently mutated oncogenic driver, yet current RAS-targeting drugs are limited by mutation specificity and acquired resistance. This study applies multimodule screening to find small molecules that inhibit RAS/RAF binding by covalently occupying a distinct site within the RAF RAS-binding domain. Structural analyses show allosteric RAF conformational disruption, blocking downstream signaling. The compounds inhibit tumor growth across multiple cancers with diverse RAS genotypes and suppress BRAFV600E melanoma progression under BRAF inhibitor resistance by preventing RAS signal reactivation, supporting a RAF-targeting design strategy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/small-molecule-rasraf-inhibitors-target-ras-driven-cancers-via-allosteric-raf-disruption/349590/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/small-molecule-rasraf-inhibitors-target-ras-driven-cancers-via-allosteric-raf-disruption/349590.png","ImageObject",300,407,{"name":92,"@type":93},"hdkawk","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are pan-RAS inhibitors still needed despite the development of KRASG12C drugs?","Question",{"text":112,"@type":113},"KRASG12C mutations represent only a minority of RAS-mutated cancers and are relatively uncommon in many solid tumors, leaving many RAS-driven cancers inadequately covered. The document also highlights the need to overcome acquired resistance to current therapies.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What mechanism do the newly identified small-molecule inhibitors use to suppress RAS-driven signaling?",{"text":117,"@type":113},"They covalently bind to a distinct site in the RAS-binding domain of RAF and allosterically disrupt RAF conformation. This prevents RAS/RAF interaction and blocks downstream signaling.",{"name":119,"@type":110,"acceptedAnswer":120},"How do the compounds perform against BRAFV600E melanoma with acquired BRAF inhibitor resistance?",{"text":121,"@type":113},"They suppress tumor growth by preventing reactivation of RAS signaling, thereby counteracting resistance that otherwise promotes RAS/RAF complex formation and downstream ERK reactivation.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},349590,1790333729,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":19,"preview_urls":144},3985747859855,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Article [https://doi.org/10.1038/s41467-026-76337-2](https://doi.org/10.1038/s41467-026-76337-2)  \nSmall-molecule RAS/RAF inhibitors target RAS-driven cancers via allosteric RAF disruption  \nReceived: 17 January 2024  \n\n| Accepted: 24 July 2026 |\n| --- |\n| |\n| Check for updates |\n\nYoko Yoshikawa 1,20, Hirokazu Kubota2,20, Shigeyuki Matsumoto 3,4,20, Yoshiteru Makino1, Takashi Kawamura5, Hitomi Yuki 6, Naoki Sakai 5, Akira Shibaike1, Megumi Okamura1, Wakako Fujimoto-Sakisaka1, Kou Honda 7, Taisuke Horikawa1, Ichiro Mori1,8, Morihito Okada9, Manabu Horikawa10,11, Kazumasa Horie 10,11, Michiyo Koyanagi-Aoi10,12, Takashi Aoi10,12,13,14,  \nTohru Kataoka 3,15, Tomoyo Okada1,16, Atsuo Tamura 7, Teruki Honma6, Takashi Kumasaka 5,17, Hiroo Koyama 2 & Fumi Shima1,18,19   \nRAS, a frequently mutated cancer-driver gene, has been the focus of intensive research, with numerous inhibitors developed to target RAS and its signalling molecules. With the advent of approved subtype-speciﬁc RAS inhibitors targeting KRASG12C mutation, the development of RAS inhibitors that are effective regardless of RAS mutation status is the next major challenge to address clinically prevalent RAS mutations and further overcome RAS-driven acquired resistance to currently available drugs. With the goal of obtaining broad-spectrum aberrant RAS-signalling inhibitors, we conduct multimodule drug screening for small-molecule compounds capable of RAS/RAF-binding inhibition. Structural studies of the hit compounds demonstrate that they covalently bind to a distinct site in the RAS-binding domain of RAF and allosterically disrupt RAF conformation, thereby preventing RAS/RAF interaction and downstream signalling. The compounds exhibit antitumour efﬁcacy against multiple cancers with varying RAS mutations, including KRAS, NRAS and HRAS, and wild-type RAS-driven cancers in preclinical models. Furthermore, they effectively suppress tumour growth of BRAFV600E-melanoma with acquired BRAF inhibitor resistance by preventing RAS signal reactivation. These ﬁndings provide a possible approach for designing RAF-targeting compounds, and the resulting molecules may serve as the basis for developing RAS/RAF-signalling inhibitors with distinct mechanisms to overcome multiple RAS-driven cancers.  \nThe oncogene products of RAS family small GTPases, HRAS, KRAS, and NRAS, function as molecular switches with active guanosine triphosphate (GTP)-bound and inactive guanosine diphosphate (GDP)-bound states. RAS·GTP initiates signalling pathways that activate downstream effectors, including RAF  \nkinases (ARAF, BRAF, and CRAF) and phosphoinositide 3-kinase (PI3K), to control cell proliferation and survival1–3. Ras with active mutations in codon 12, 13, and 61 constitutively activates these downstream effectors for their oncogenic function, leading to tumorigenesis3,4.  \nA full list of afﬁliations appears at the end of the paper. e-mail: [sfumi@med.kobe-u.ac.jp](sfumi@med.kobe-u.ac.jp); [fumishima0817@gmail.com](fumishima0817@gmail.com)  \nRAS mutations are found in approximately 25% of all human cancers and are especially common in pancreatic cancers (approximately90%) and colorectal cancers(approximately45%);hence, RAS isone of the main targets for antitumour drug development, and over the past several decades, a great deal of effort has been devoted to the pharmacotherapy of RAS proteins4–8. Researchers have also focused on targeting other important downstream molecules in the RAS signalling pathway, such as RAF and MEK (MAPK/ERK kinase)8,9. However, drugs targeting these downstream molecules have failed to control RAS-driven cancers. Rather, some BRAF inhibitors have been reported to cause paradoxical activation of RAS signalling in RAS-driven cancers, and long-term treatment of BRAF-activated (BRAFV600E) melanoma with BRAF inhibitors leads to paradoxical activation of extracellular signal-regulated kinase (ERK) or acquired drug resistance by promoting RAS/RAF complex formation and dimerization ","cbCaiqYkvFn1dFeR","https://ap.wps.com/l/cbCaiqYkvFn1dFeR","pdf",5353646,"English","# Background\n## RAS mutations and limitations of existing therapies\n## Downstream RAF/MEK targeting challenges\n# Covalent allosteric RAF disruption strategy\n## Screening for RAS/RAF-binding inhibitors\n## Structural mechanism of inhibitor action\n# Preclinical efficacy across cancer contexts\n## Multiple RAS mutation types\n## BRAFV600E melanoma with acquired resistance","[{\"question\":\"Why are pan-RAS inhibitors still needed despite the development of KRASG12C drugs?\",\"answer\":\"KRASG12C mutations represent only a minority of RAS-mutated cancers and are relatively uncommon in many solid tumors, leaving many RAS-driven cancers inadequately covered. The document also highlights the need to overcome acquired resistance to current therapies.\"},{\"question\":\"What mechanism do the newly identified small-molecule inhibitors use to suppress RAS-driven signaling?\",\"answer\":\"They covalently bind to a distinct site in the RAS-binding domain of RAF and allosterically disrupt RAF conformation. This prevents RAS/RAF interaction and blocks downstream signaling.\"},{\"question\":\"How do the compounds perform against BRAFV600E melanoma with acquired BRAF inhibitor resistance?\",\"answer\":\"They suppress tumor growth by preventing reactivation of RAS signaling, thereby counteracting resistance that otherwise promotes RAS/RAF complex formation and downstream ERK reactivation.\"}]","Small-molecule RAS/RAF inhibitors target RAS-driven cancers via allosteric RAF disruption | PDF",1790084437,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/da143b92188cce6951bcf2a22ec15458.webp",983,1305,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9429e65108b34423f7ccb26e2b0d985e.webp",982,1304,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/87a0155903eda2ca24b86df995a038ab.webp",981,1303,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/632c1f7d08f3c0ce1b95164be6d6c2b1.webp",980,1301]